---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-001502"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:41:29.920071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences reports $336M cash; outlines 2026 pipeline milestones including JADE101 Phase 2

## Summary
- Cash, cash equivalents and investments ~$336M as of Dec 31, 2025; funds operations into H1 2028.
- JADE101 Phase 1 interim data expected H1 2026; Phase 2 in IgAN to start mid-2026 with preliminary data in 2027.
- JADE201 (anti-BAFF-R) first-in-human study in RA expected Q2 2026; interim data in 2027.
- JADE301 nominated; preclinical; Phase 1 expected H1 2027; details disclosed H2 2026.
- Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2026.

## SEC filing metadata
- accession: 0001193125-26-001502
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526001502/0001193125-26-001502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526001502/d93206d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-001502
- JSON: https://secwatch.observer/filing/0001193125-26-001502.json
- Plain text: https://secwatch.observer/filing/0001193125-26-001502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.